Based on these resistant mechanisms, new and irreversible EGFR-TKIs have been found to be clinically effective in inhibiting the growth of NSCLC tumors with resistance to earlier EGFR-TKIs [6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.